Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Sharon Mates Biography and Net Worth

CEO of Intra-Cellular Therapies

As Founder, Chairman and CEO of Intra-Cellular Therapies (ITCI), Dr. Mates leads Intra-Cellular Therapies, a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative drugs that address underserved medical needs in complex psychiatric and neurologic diseases.

Dr. Mates has more than 25 years of experience leading public and private companies with a steadfast commitment to cutting-edge science and research to discover innovative approaches to treating disease. Prior to co-founding ITCI in 2002, she was President and board member of North American Vaccine Inc. and its predecessor companies for almost a decade, during which time she oversaw the development and approval of pediatric vaccines. Throughout her career, she has held numerous advisory and board positions including a current board appointment to Biotechnology Innovation Organization Emerging Company Section (BIO ECS). Previous appointments include chairman of the New York Biotechnology Association, Board of Visitors of the Biotechnology Institute of the University of Maryland, and member of the Harvard School of Public Health Advisory Council of the Center for Society and Health.

Dr. Mates received her B.S. from The Ohio State University and her Ph.D. from the University of Washington. She completed her postdoctoral fellowships at the Massachusetts General Hospital and Harvard Medical School.

What is Sharon Mates' net worth?: The estimated net worth of Sharon Mates is at least $76.01 million as of March 7th, 2024. Dr. Mates owns 1,050,309 shares of Intra-Cellular Therapies stock worth more than $76,010,862 as of April 19th. This net worth approximation does not reflect any other investments that Dr. Mates may own. Additionally, Dr. Mates receives a salary of $2,230,000.00 as CEO at Intra-Cellular Therapies. Learn More about Sharon Mates' net worth.
How old is Sharon Mates?: Dr. Mates is currently 71 years old. There are 6 older executives and no younger executives at Intra-Cellular Therapies. Learn More on Sharon Mates' age.
What is Sharon Mates' salary?: As the CEO of Intra-Cellular Therapies, Inc., Dr. Mates earns $2,230,000.00 per year. Learn More on Sharon Mates' salary.
How do I contact Sharon Mates?: The corporate mailing address for Dr. Mates and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected]. Learn More on Sharon Mates' contact information.
Has Sharon Mates been buying or selling shares of Intra-Cellular Therapies?: Sharon Mates has not been actively trading shares of Intra-Cellular Therapies over the course of the past ninety days. Most recently, Sharon Mates sold 20,565 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $65.21, for a transaction totalling $1,341,043.65. Following the completion of the sale, the chief executive officer now directly owns 1,050,309 shares of the company's stock, valued at $68,490,649.89. Learn More on Sharon Mates' trading history.
Who are Intra-Cellular Therapies' active insiders?: Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), Rory Riggs (Director), and Robert Van Nostrand (Director). Learn More on Intra-Cellular Therapies' active insiders.
Are insiders buying or selling shares of Intra-Cellular Therapies?: During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 682,285 shares worth more than $43,934,823.19. The most recent insider tranaction occured on March, 11th when CEO Sharon Mates sold 20,565 shares worth more than $1,341,043.65. Insiders at Intra-Cellular Therapies own 3.4% of the company. Learn More about insider trades at Intra-Cellular Therapies.
Information on this page was last updated on 3/11/2024.

Sharon Mates Insider Trading History at Intra-Cellular Therapies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2024	Sell	20,565	$65.21	$1,341,043.65	1,050,309
3/7/2024	Sell	40,712	$66.50	$2,707,348.00	1,050,309
2/26/2024	Sell	22,590	$69.79	$1,576,556.10	1,050,309
1/18/2024	Sell	67,917	$65.19	$4,427,509.23	1,050,309
1/16/2024	Sell	75,361	$67.25	$5,068,027.25	1,050,309
9/18/2023	Sell	55,587	$53.76	$2,988,357.12	1,094,722
3/13/2023	Sell	20,565	$44.99	$925,219.35	1,130,309
3/10/2023	Sell	41,770	$43.15	$1,802,375.50	1,130,309
2/24/2023	Sell	22,590	$47.03	$1,062,407.70	1,100,309
2/21/2023	Sell	27,848	$46.83	$1,304,121.84	1,100,309
12/13/2022	Sell	33,083	$55.00	$1,819,565.00	1,100,309
2/24/2022	Sell	22,589	$51.98	$1,174,176.22
2/22/2022	Sell	27,847	$55.39	$1,542,445.33
1/10/2022	Sell	41,896	$40.78	$1,708,518.88
10/18/2021	Sell	8,192	$40.00	$327,680.00
10/15/2021	Sell	40,392	$40.00	$1,615,680.00
2/19/2021	Sell	27,847	$39.23	$1,092,437.81	1,161,239
1/11/2021	Sell	41,896	$32.01	$1,341,090.96	1,175,288
1/4/2021	Sell	48,341	$31.30	$1,513,073.30
11/4/2020	Sell	50,000	$25.00	$1,250,000.00	1,163,392
1/9/2020	Sell	41,895	$26.16	$1,095,973.20	1,204,707
1/6/2020	Sell	45,598	$30.28	$1,380,707.44	1,182,366
1/2/2020	Sell	17,478	$32.45	$567,161.10	1,156,185
1/7/2019	Sell	6,604	$12.43	$82,087.72	1,190,909
1/4/2019	Sell	45,598	$11.45	$522,097.10	1,190,909
1/2/2019	Sell	17,478	$11.09	$193,831.02	1,156,185
1/8/2018	Sell	6,604	$17.48	$115,437.92	1,088,707
1/5/2018	Sell	11,257	$17.08	$192,269.56	1,099,964
10/30/2017	Sell	18,750	$15.75	$295,312.50	1,107,457
1/5/2017	Sell	4,081	$16.55	$67,540.55	1,088,707
12/11/2015	Sell	51,500	$53.87	$2,774,305.00	1,086,185

Sharon Mates Buying and Selling Activity at Intra-Cellular Therapies

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $72.37

$70.94

$74.56

50 Day Range

MA: $69.31

$64.37

$79.84

2 Week Range

Now: $72.37

$45.50

$84.89

Volume

2,189,204 shs

Average Volume

1,188,995 shs

Market Capitalization

$7.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

Sharon Mates Biography and Net Worth

What is Sharon Mates' net worth?

How old is Sharon Mates?

What is Sharon Mates' salary?

How do I contact Sharon Mates?

Has Sharon Mates been buying or selling shares of Intra-Cellular Therapies?

Who are Intra-Cellular Therapies' active insiders?

Are insiders buying or selling shares of Intra-Cellular Therapies?